# 1. Financial Performance ## A. Key Figures * Consolidated Revenue (9M FY26): INR6,763 Cr (+17.1%) * Hospital Revenue (9M FY26): INR5,749 Cr (+19.1%) · Operating Margin: 22.2% (from 20%) * **Q3 Revenue:** **INR371 Cr** (+8.3% YoY) · **9M Revenue (Dec-25):** **INR1,139 Cr** (+7.7%) * **Q3 EBITDA:** **INR505 Cr** (+34.8% YoY) · **Margin:** 22.3% (from 19.4%) * **9M Operating EBITDA:** **INR1,553 Cr** · **Margin:** 23% (+300 bps) * **Q3 PBT (ex-exceptional):** **INR312 Cr** (+9%) · **Reported PAT:** **INR197 Cr** (from INR250 Cr) * **Net Debt (Dec 31, 2025):** **INR2,547 Cr** · **Net Debt/EBITDA:** 24x ## B. Revenue Growth * **Stable Top-Line Trajectory:** Consolidated revenue shows modest growth, while select segments like Q3 and 9-month gross revenue demonstrate **accelerating momentum** with strong double-digit underlying trends. * **Hospital Business Resilience:** Core hospital revenue grew steadily, with early signs of **profitability stabilization** after prior-year margin pressure. * **Q3 Inflection:** Recent quarter reflects **notable improvements in growth and profitability**, driven by network expansion and operational discipline. ## C. EBITDA Margins * **Broad-Based Margin Expansion:** Operating EBITDA margin improved 300 bps over 9 months, with **existing units delivering significantly above-average margin gains**, partially diluted by new unit ramp-up. * **High-Contributing Units Rising:** **13 hospitals** now generate **77% of hospital revenues** with margins above 20%, up from 10 hospitals contributing 73%, signaling improved asset productivity. * **Q3 Profitability Strength:** EBITDA growth outpaced revenue with **8% YoY increase** and margin expansion, led by hospital business margin jump to 7% and strong operating leverage. * **Future Margin Upside:** **~150 bps further expansion** is feasible, primarily via brownfield optimization at FMRI and elimination of intercompany cost drag. ## D. Profit After Tax * **PAT Impact from One-Offs:** Reported profit declined due to **INR55 Cr one-time expense** from New Labour Codes, though underlying earnings (PBT) grew 9%, highlighting core profitability strength. * **Exceptional Items Distortion:** Net exceptional loss of **INR46 Cr** masked operational gains, with a **reversal of INR9 Cr impairment** partially offsetting the charge. ## E. Balance Sheet * **Debt-Funded Strategic Acquisitions:** Net debt increased to INR2,547 Cr (24x EBITDA) to finance key deals including **Agilus Diagnostics, Fortis brand, and Shrimann Hospital**. * **Post-Acquisition Leverage:** Debt now ~INR3,000 Cr against ~INR1,500 Cr EBITDA, but management retains **capacity and intent to lever further for growth**. * **Equity Infusion Expected:** IHH’s stake increase restriction lifted; **preferential allotment likely within 3–6 months** to strengthen equity base by at least 5%, supporting future expansion. * **Strategic Balance Sheet Management:** Focus on creating headroom amid favorable market conditions, with **investment timing clarity expected in 3–6 months**. --- # 2. Occupancy & Utilization ## A. Key Figures * **Hospital Occupancy:** **67%** Q3 FY26 (flat YoY) · **69%** 9M FY26 (flat YoY) * **Occupied Beds:** **3,189** in Q3 FY26 (+14% YoY) · **+3% OBD growth** driven by expansion and optimization * ARPOB: ₹2.56 Cr annualized (+4.5%) * **Bed Additions:** **250 organic brownfield beds** added in 9M FY26 · **+50 beds** expected from Noida by year-end ## B. Hospital Occupancy * **Stable Utilization Amid Expansion:** Despite flat system-wide occupancy, underlying demand remains strong with **14% growth in occupied beds**, reflecting meaningful capacity absorption. * **Clinical Staff Scalability:** FMRI’s physician team is sufficient for planned 200-bed expansion, supported by **~80% utilization** of current capacity, signaling efficient human resource leverage. * **Mixed Facility Performance:** Strong momentum at Shalimar Bagh, FMRI, and Mulund (over **65% occupancy**), while BG Road lags and remains a turnaround focus. * **Ramp-Up Outlook:** Confidence in near-term absorption of first 100 new beds; timing of second phase contingent on ramp velocity, possibly within FY26 or FY27. ## C. Bed Count Growth * **Sustained Organic Expansion:** Bed network growing through brownfield additions in Jalandhar, Greater Noida, and Noida, with minor gains in Adayar and existing centers. ## D. ARPOB Trends * **Revenue Quality Upgrades:** ARPOB growth driven equally by **price realization (50%)** and **case mix enrichment (50%)**, particularly from robotic surgeries and complex procedures. * **Oncology-Driven Upside:** Future ARPOB expansion expected to accelerate via high-margin oncology services (IP/daycare), with **4–5% annual growth** forecast over next two years. * **Diagnostic Volume Growth:** Testing volumes rose significantly in 9M FY26, fueled by **550+ new customer touchpoints**, enhancing downstream referral and revenue potential. --- # 3. Network & Capacity ## A. Key Figures * **Beds Added:** **750** operational beds (+~250 brownfield, +~500 acquisition) * **Customer Touch Points:** **4,370** as of Dec 31, 2025 (+175 in quarter) * Bed CAGR (FY25–FY30): ~10.7% (peaking in FY26), moderating to 6–6.5% post-FY26 * **Targeted Bed Additions:** **~430** consolidated beds by FY27 (ex. new M&A) * **Acquisition Cost:** **₹430 Cr** for 125-bed People Tree Hospital, Bengaluru ## B. Brownfield Expansion * **Flagship Expansion On Track:** FMRI to add **200+ beds** in phases, with first 100-bed phase now targeted for April due to regulatory delays; minimal incremental capex required. * **Multi-City Capacity Buildout:** Over **400 brownfield beds** planned for next fiscal, led by FMRI, with approved expansions underway at Shalimar Bagh and in pipeline for Jalandhar, TMI, and Faridabad. * **Specialty-Led Growth:** Jaipur and Hyderabad expansions focused on **oncology** to drive cross-specialty volume; Jaipur’s onco plan revived after prior hold. * **Underutilized Asset Upgrade:** People Tree Hospital, Bangalore (125 beds) to be expanded to **300 beds** over 3–4 years to meet Fortis super speciality standards. ## C. Acquisition Additions * **Strategic Cluster Expansion:** 100% acquisition of **125-bed People Tree Hospital, Bengaluru** (₹430 Cr) provides prime location and expansion runway to 300+ beds, offering significant cost advantage vs. greenfield. * **Acquisition-Driven Scale:** Over **500 beds added via M&A**, including Jalandhar and Greater Noida; pipeline remains active with focus on **in-cluster deals** to deepen market presence. * **Rapid Network Reach:** Customer touch points expanded by **175 in quarter**, reflecting aggressive footprint growth across labs and HLMs in focus and emerging markets. ## D. Future Bed Pipeline * **Near-Term Commissioning:** Noida beds to open imminently; FMRI remains key near-term catalyst with April target, while all other projects expected to proceed without delay. * **Sustained Expansion Trajectory:** FY26 marks peak bed addition year, with **~430 beds** expected by FY27 under current plan, supported by both brownfield and acquisition momentum. --- # 4. Product & Service Mix ## A. Key Figures * **Preventive Health Mix:** **12%** of revenue (Q3 FY'26) (+200 bps YoY) · **Specialized Portfolio Mix:** **35%** (Q3 FY'26) (+200 bps YoY) * **Test Volumes:** **9.9 Mn** tests (Q3 FY'26) (+3.6% YoY) · Prior year: **9.6 Mn** tests ## B. Specialty Revenue Mix * **Portfolio Shift:** Continued strategic shift toward higher-value segments with **robust growth in preventive and specialized offerings**, reflecting strong demand for advanced care. * **Diversified Momentum:** Revenue growth broad-based across **routine, wellness, and specialized lines**, indicating resilient demand and effective market penetration. * **International Stability:** International patient revenue remains steady at **8–9%** of total, though geopolitical dynamics continue to limit expansion potential. * **Pricing Tailwinds:** **Positive pricing realization in CGHS**, while ECHS improvements await regulatory clarity but show favorable early signals. ## C. Diagnostic Offerings * **Innovation Pipeline:** Launched **CNS biopsy with Reflex to IHC**, **RA extended panel**, and **acute leukemia panel**, strengthening capabilities in neuro-oncology, autoimmunity, and hemato-oncology. * **Genomics Scale-Up:** **Illumina NovaSeq X** installed in Mumbai, enabling high-throughput NGS across oncology, infectious diseases, and rare disorders, positioning the company as a leader in advanced diagnostics. * **Operational Efficiency:** Automation, digital tracking, and workflow enhancements have reduced turnaround times and improved customer experience amid expanding service complexity. --- # 5. Segment & Cluster Performance ## A. Key Figures * **Digital Channel Revenues:** **30%** of total hospital revenues (Q3 FY26) (+19% YoY) * **B2C-B2B Revenue Mix:** **52-48** * **O&M Fee Income (Gleneagles):** **₹5 Cr** (Q3 FY26) * **Acquisition Contribution:** **~4%** of revenue growth from Jalandhar and Greater Noida ## B. Regional Performance * **International Expansion Push:** Targeting scalable growth in West/East Africa, Middle East, and Central Asia via direct marketing and information centers. * **Cluster Development:** Hyderabad established as a new strategic cluster despite competitive pressures; Kengeri facility performing well, while another Bangalore unit needs turnaround. ## C. B2C-B2B Mix * **Digital Channel Momentum:** Digital platforms driving strong double-digit revenue growth and now represent a material portion of total hospital income. * **Balanced Revenue Model:** Near-even B2C-B2B split reflects diversified demand and effective outreach across patient and institutional segments. ## D. Gleneagles Integration * **Stable O&M Contribution:** Gleneagles delivered a full-quarter run-rate equivalent of ₹5 Cr in fees, with operations fully integrated into Fortis management. * **Operational Challenges Persist:** Nine-month revenue trend was slightly negative due to clinician attrition and leadership changes, though stabilization is expected from next fiscal. * **Structural Alignment Achieved:** Regional leadership strengthened and Gleneagles in Bangalore placed under existing cluster oversight, ensuring organizational coherence. * **Mumbai Expansion Under Review:** Ongoing discussions on including Mumbai Hospital in O&M agreement; no decision yet. --- # 6. Risks & Operational Challenges ## A. Key Figures * **Occupancy Drag from New Units:** **50 bps** impact from Greater Noida, Adayu, and Noida ## B. New Unit Drag * **New Facility Drag:** Margins pressured by early-stage units, with **Greater Noida and Manesar** at breakeven or minimal EBITDA despite strong potential for improvement over time. * **Performance Divergence:** **Jalandhar** delivers flagship-level performance with **>25% EBITDA margin**, highlighting unit-specific rather than systemic operational challenges. * **Limited Systemic Risk:** Underperformance is isolated to small or new units; **Gleneagles hospitals require tailored turnarounds**, not broad restructuring. ## C. Talent Retention * **Clinical Hiring Confidence:** Fortis expects strong talent inflow for **Bangalore expansion**, backed by proven success at Nagarbhavi, which achieves **>25% EBITDA margin**. * **Remuneration Adjustments:** NCR region sees targeted doctor payout revisions to retain talent, but **strong revenue growth fully offsets cost pressures** with negligible margin impact. * **Jaipur Margin Pressure:** Persistent weakness linked to **absence of oncology business**, despite available infrastructure, representing a key fixable gap. ## D. Regulatory Delays * **Bangalore Land Expansion Delayed:** Regulatory hurdles push commercialization **beyond FY '28**, with timeline of **24–30 months** now expected. * **Pending Government Clarity:** Benefits from **CGHS super specialty registration** and **ECHS drug pricing** remain unquantifiable pending policy decisions in the next year. * **Growth Amid Competition:** Company maintains aggressive expansion stance despite crowded corporate hospital landscape. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth (FY '27):** **~20%** expected (ongoing momentum) * **Oncology Unit Timeline:** **18–24 months** to establish ## B. Revenue Forecast * **Sustained Growth Trajectory:** Top-line expansion projected at around 20% for FY '27, underpinned by strong market momentum and adoption tailwinds. * **Delayed Rate Hike Benefits:** CGHS/ECGS rate increases expected to boost revenues meaningfully, though impact delayed and likely materializing fully only by **FY '27**. ## C. Margin Expansion * **Multi-Year Margin Upside:** Management expects current trends in profitability improvement to persist for at least the next two fiscal years. ## D. Capex Plans * **Long-Term Growth Drivers:** Expansion fueled by rising demand for preventive health panels and corporate wellness programs amid growing health awareness. * **Project Pipeline Advancing:** Oncology unit development ongoing, with **Jaipur allocation set for next fiscal**; new sites in Mohali and Shalimar Bagh in planning, capex details pending finalization.